1. JAK/STAT Signaling Protein Tyrosine Kinase/RTK
  2. EGFR
  3. Panitumumab

Panitumumab  (Synonyms: ABX-EGF)

Cat. No.: HY-P99041 Purity: 99.77%
Technical Support

Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer.

For research use only. We do not sell to patients.

CAS No. : 339177-26-3

Size Price Stock Quantity
Free Sample (100 μg)   Apply Now  
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Panitumumab:

Top Publications Citing Use of Products

    Panitumumab purchased from MedChemExpress. Usage Cited in: Sci Rep. 2022 Jul 7;12(1):11561.  [Abstract]

    HeLa cells were pretreated with 100 nM cetuximab (Cmab) or 30 nM panitumumab (Pmab) for 10 min and then stimulated with 20 ng/mL TNF-α for 15 or 60 min. The expression of the indicated proteins was detected by immunoblotting.

    Panitumumab purchased from MedChemExpress. Usage Cited in: Sci Rep. 2022 Jul 7;12(1):11561.  [Abstract]

    Panitumumab (100 nM, 25 min) was internalized upon stimulation with TNF-α (20 ng/mL, 15 min) in HeLa cells.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer[1][2][4].

    Isotype

    Human IgG2 kappa

    Recommend Isotype Controls
    Species Reactivity

    Human

    IC50 & Target

    EGFR

    In Vitro

    Panitumumab (2 nM-2 μM, 3 h) inhibits ligand-dependent autophosphorylation in EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells[3].
    Panitumumab (0-200 μg/mL, 48 h) inhibits the proliferation of DLD-1 cells[4].
    Panitumumab (80 μg/mL, 24 h) increase beclin-1 (a marker of autophagy) levels in Caco-2 cells and DLD-1 cells[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Western Blot Analysis[3]

    Cell Line: EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells
    Concentration: 2, 20, 200, 2000 nM
    Incubation Time: 3 h
    Result: Inhibited ligand-induced autophosphorylation of EGFR.
    In Vivo

    Panitumumab (25-500 μg per mouse, i.p., twice a week) inhibits tumor growth in the xenograft models of NCI-H1975 and NCI-H1650 in mice[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: NCI-H1975 and NCI-H1650 xenografts[3]
    Dosage: 25, 100, or 500 μg/mouse
    Administration: Intraperitoneal injection (i.p.), twice a week
    Result: Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation.
    Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.
    Gene ID

    1956  [NCBI]

    Accession

    P00533-1

    Application

    ELISA, FACS, Functional assay

    Conjugated

    Unconjugated

    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.

    Molecular Weight

    144.32 kDa

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Panitumumab]

    Shipping

    Shipping with dry ice.

    Formulation

    Please refer to the lot-specific COA for specific buffer information.

    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.

    Format
    • Human IgG2 kappa
    Biological Activity
    • Immobilized EGFR Protein, Human can bind Panitumumab. The EC50 for this effect is 47.19 ng/mL.
    • Panitumumab has a significant ADCP effect on CHOK1-human EGFR cells in a dose-dependent manner.The EC50 for this effect is 130.4 ng/mL.
    Purity & Documentation

    Purity: 99.77%

    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Panitumumab
    Cat. No.:
    HY-P99041
    Quantity:
    MCE Japan Authorized Agent: